Skip to main content
. 2023 Jan 6;26:100573. doi: 10.1016/j.lanepe.2022.100573

Fig. 3.

Fig. 3

Cumulative use of systemic therapies during the first three years since the diagnosis of HR+/HER2− advanced breast cancer with 95% confidence intervals, per period of diagnosis. See Supplementary Fig. S1 for the graphs of the cumulative use of these systemic agents.